“…A PIM1-specific inhibitor could potentially be used to enhance the immunosuppressive activity of Treg cells through downregulating the phosphorylation of FOXP3-Ser422 during ex vivo preparation of Treg cells, 54 while PP1-specific inhibitor may work reversely and weaken the immunosuppressive activity of Treg cells; 60 STUB1-specific inhibitors, may stabilize Treg cells through preventing FOXP3 ubiquitination and degradation, whereas USP7-specific inhibitor treated Treg cells may lose their stability through promoting the process; 31,55 SIRT1/HDAC9 inhibitors would enhance the activity of Treg cells through promoting FOXP3 acetylation and facilitating its stability or activity upregulation, while P300/TIP60 inhibitors may abolish the process and promote FOXP3 degradation mediated by FOXP3 ubiquitination. 53,57,75,76 Along with the accumulation of our knowledge on the molecular mechanism of Treg immunosuppressive activity, we expect that in the next few years, increasingly safe and effective compounds, which could aid the ex vivo expansion of Treg cells by helping to maintain their stable function in vivo, will be identified and advance into clinical trials for the treatment of autoimmune diseases and other inflammatory diseases.…”